Neurogene (NASDAQ:NGNE – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $55.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 50.15% from the company’s previous close. Several other analysts also […]